Results 301 to 310 of about 678,002 (383)

Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paltusotine is a novel, nonpeptide, selective somatostatin receptor 2 agonist in development for the treatment of acromegaly and carcinoid syndrome. This study investigated the mass balance, routes of excretion, absolute bioavailability and metabolite profile of orally administered paltusotine.
Rosa Luo, Ajay Madan, Christine T. Ferrara‐Cook, Deepak Dalvie, Lance Goulet, R. Scott Struthers, Alan S. Krasner   +6 more
wiley   +1 more source

Association between body composition components and electrocardiogram parameters: results from the Fasa Adults Cohort Study (FACS). [PDF]

Eur J Med Res
Sharafi M, Afrashteh S, Farjam M, Keshavarzian O, Annabi Toolgilani MA, Aboughadare H, Dastmanedh S, Moghaddam MT.   +7 more
europepmc   +1 more source

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Dipeptidyl peptidase‐1 (DPP‐1) inhibitors have been studied for the treatment of neutrophil‐mediated inflammatory diseases including bronchiectasis, bronchial asthma and cystic fibrosis. This study evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of DPP‐1 inhibitor HSK31858 in healthy Chinese volunteers.
Yuhao Wang, Chao Yu, Mengyue Hu, Lu Wang, Meixia Chen, Hanmo Liu, Nan Wu, Jie Hou   +7 more
wiley   +1 more source

A multicenter pragmatic implementation study of AI-ECG-based clinical decision support software to identify low LVEF: Clinical trial design and methods. [PDF]

Am Heart J Plus
Lopez-Jimenez F, Alger HM, Attia ZI, Barry B, Chatterjee R, Dolor R, Friedman PA, Greene SJ, Greenwood J, Gundurao V, Hackett S, Jain P, Kinaszczuk A, Mehta K, O'Grady J, Pandey A, Pullins C, Puranik AR, Ranganathan MK, Rushlow D, Stampehl M, Subramanian V, Vassor K, Zhu X, Awasthi S.   +24 more
europepmc   +1 more source

The Effect of Long-Acting Nitrates on Ambulatory ECG Changes in Patients with Angina Pectoris Treated for 1 Week

, 1983
Keith A.A. Fox, John Deanfield, Christine Wright, P Ribeiro, A. Maseri   +4 more
openalex   +1 more source

Anticoagulation intensity and outcomes among southeast‐Asians with moderate‐to‐severe mitral valve stenosis

British Journal of Clinical Pharmacology, EarlyView.
Objective To determine the optimal anticoagulation intensity of warfarin in a South‐East Asian population with moderate‐to‐severe rheumatic mitral stenosis. Methods A multicentre, retrospective study examined patients with rheumatic mitral stenosis who had not undergone valve replacement or repair and required long‐term warfarin therapy at two ...
Punyawee Puchsaka, Wipharak Rattanavipanon, Sararat Phetroong, Rudeekorn Ue‐sethasakdhi, Suparat Wattanasombat, Wattana Wongtheptien, Surakit Nathisuwan   +6 more
wiley   +1 more source

Novel accurate classification system developed using order transition pattern feature engineering technique with physiological signals. [PDF]

Sci Rep
Gelen MA, Barua PD, Tasci I, Tasci G, Aydemir E, Dogan S, Tuncer T, Acharya UR.   +7 more
europepmc   +1 more source

Computer Assisted ECG Analysis by HP-5600C System (Application to AMHTS)

, 1980
河村 博, 曾我 れい子, 高田 美智子, 酒向 俊雄, 清水 智恵子, 松尾 登, 酒井 正衛, 木村 英道, 熊崎 信子   +8 more
openalex   +2 more sources

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano   +4 more
wiley   +1 more source

Explainable machine learning model based on EEG, ECG, and clinical features for predicting neurological outcomes in cardiac arrest patient. [PDF]

Sci Rep
Niu Y, Chen X, Fan J, Liu C, Fang M, Liu Z, Meng X, Liu Y, Lu L, Fan H.   +9 more
europepmc   +1 more source